Quick Answer
Foghorn Therapeutics Inc. reported Earnings Per Share Diluted of $1.18 (loss) per share for the year ending 2025.
- Foghorn Therapeutics Inc. showed an increase of +25.3% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Foghorn Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $2.90 (loss) per share | Q3 2020: $3.12 (loss) per share | Q1 2021: $0.62 (loss) per share | Q2 2021: $0.63 (loss) per share | Q3 2021: $0.71 (loss) per share | Q1 2022: $0.65 (loss) per share | Q2 2022: $0.66 (loss) per share | Q3 2022: $0.62 (loss) per share | Q1 2023: $0.73 (loss) per share | Q2 2023: $0.70 (loss) per share | Q3 2023: $0.34 (loss) per share | Q1 2024: $0.59 (loss) per share | Q2 2024: $0.45 (loss) per share | Q3 2024: $0.31 (loss) per share | Q1 2025: $0.30 (loss) per share | Q2 2025: $0.28 (loss) per share | Q3 2025: $0.25 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Foghorn Therapeutics Inc.'s Earnings Per Share Diluted has grown by 81.1%.
- Historical annual values: Fiscal year 2025: $1.18 (loss) per share | Fiscal year 2024: $1.58 (loss) per share | Fiscal year 2023: $2.34 (loss) per share | Fiscal year 2022: $2.62 (loss) per share | Fiscal year 2021: $2.73 (loss) per share | Fiscal year 2020: $6.23 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: